4.5 Review

Recent advances in the understanding of the aetiology and therapeutic strategies in burning mouth syndrome: Focus on the actions of cannabinoids

Journal

EUROPEAN JOURNAL OF NEUROSCIENCE
Volume 55, Issue 4, Pages 1032-1050

Publisher

WILEY
DOI: 10.1111/ejn.14712

Keywords

burning mouth syndrome; cannabinoids; cannabis; endocannabinoid system; hormonal; immunological; neuropathic orofacial pain; psychological; therapeutics

Categories

Funding

  1. Enterprise Ireland [IP/2018/0740]

Ask authors/readers for more resources

Burning mouth syndrome (BMS) is a neuropathic pain disorder characterized by a burning sensation on oral mucosal surfaces, along with xerostomia, dysgeusia, and tingling or paraesthetic sensations. The classification of the disorder has posed a diagnostic challenge for clinicians/dentists. Recent research has provided insights into the pathophysiological mechanisms and therapeutic strategies for BMS, but controlled clinical studies are needed to support the effectiveness of these approaches. The potential of cannabis-based therapeutics in managing BMS patients is also explored.
Burning mouth syndrome (BMS) is a neuropathic pain disorder associated with a burning sensation on oral mucosal surfaces with frequently reported xerostomia, dysgeusia and tingling or paraesthetic sensations. However, patients present no clinically evident causative lesions. The poor classification of the disorder has resulted in a diagnostic challenge, particularly for the clinician/dentist evaluating these individuals. Major research developments have been made in the BMS field in recent years to address this concern, principally in terms of the pathophysiological mechanisms underlying the disorder, in addition to therapeutic advancements. For the purpose of this review, an update on the pathophysiological mechanisms will be discussed from a neuropathic, immunological, hormonal and psychological perspective. This review will also focus on the many therapeutic strategies that have been explored for BMS, including antidepressants/antipsychotics, non-steroidal anti-inflammatories, hormone replacement therapies, phytotherapeutic compounds and non-pharmacological interventions, overall highlighting the lack of controlled clinical studies to support the effectiveness of such therapeutic avenues. Particular focus is given to the cannabinoid system and the potential of cannabis-based therapeutics in managing BMS patients.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available